There were 35 patients enrolled in each oral insulin arm of the trial, and 36 in placebo. Results showed that the total number of patients achieving a hemoglobin A1c (HbA1c) decrease of more than 1.1% among the 35 patients dosed at the 10 mg QID dose of oral insulin was statistically significantly higher than in the 36 placebo patients (p=0.0368).